Gastrointestinal transit time, glucose homeostasis and metabolic health: Modulation by dietary fibers

Nutrients

Volumn 10, Issue 3, 2018, Pages

  Müller, Mattea ^a   Canfora, Emanuel E ^a   Blaak, Ellen E ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dietary fiber; Gastrointestinal transit; Microbiota; Obesity; Type 2 diabetes

Indexed keywords

GLUCOSE; INSULIN; INULIN; PREBIOTIC AGENT; BIOLOGICAL MARKER;

BACTERIAL FLORA; CARDIOMETABOLIC RISK; CLOSTRIDIACEAE; CLOSTRIDIUM; COLON MOTILITY; DIETARY FIBER; ENERGY METABOLISM; ESOPHAGUS; FOOD INTAKE; GASTROINTESTINAL TRANSIT; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INTESTINE FLORA; INTESTINE FUNCTION; INTESTINE MUCOSA; MEAL; METABOLIC DISORDER; METABOLISM; METHANOBREVIBACTER; MOTONEURON; MUCOSAL IMMUNITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OPPORTUNISTIC INFECTION; PHENOTYPE; REVIEW; RISK FACTOR; STOMACH EMPTYING; ADMINISTRATION AND DOSAGE; ANIMAL; BLOOD; GASTROINTESTINAL TRACT; HEALTHY DIET; HOMEOSTASIS; NUTRITIONAL STATUS; PATHOPHYSIOLOGY; RISK REDUCTION;

ANIMALS; BIOMARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY FIBER; GASTROINTESTINAL TRACT; GASTROINTESTINAL TRANSIT; HEALTHY DIET; HOMEOSTASIS; HUMANS; NUTRITIONAL STATUS; OBESITY; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 85042658246     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu10030275     Document Type: Review

References (146)

1. Fandriks, L. Roles of the gut in the metabolic syndrome: An overview. J. Intern. Med. 2017, 281, 319–336. [CrossRef] [PubMed]
2. Holst, J.J.; Gribble, F.; Horowitz, M.; Rayner, C.K. Roles of the gut in glucose homeostasis. Diabetes Care 2016, 39, 884–892. [CrossRef] [PubMed]
3. Falony, G.; Joossens, M.; Vieira-Silva, S.; Wang, J.; Darzi, Y.; Faust, K.; Kurilshikov, A.; Bonder, M.J.; Valles-Colomer, M.; Vandeputte, D.; et al. Population-level analysis of gut microbiome variation. Science 2016, 352, 560–564. [CrossRef] [PubMed]
4. Canfora, E.E.; Jocken, J.W.; Blaak, E.E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 2015, 11, 577–591. [CrossRef] [PubMed]
5. Kahn, S.E.; Hull, R.L.; Utzschneider, K.M. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006, 444, 840–846. [CrossRef] [PubMed]
6. Parker, E.D.; Liu, S.; Van Horn, L.; Tinker, L.F.; Shikany, J.M.; Eaton, C.B.; Margolis, K.L. The association of whole grain consumption with incident type 2 diabetes: The women’s health initiative observational study. Ann. Epidemiol. 2013, 23, 321–327. [CrossRef] [PubMed]
7. InterAct Consortium. Dietary fibre and incidence of type 2 diabetes in eight European countries: The epic-interact study and a meta-analysis of prospective studies. Diabetologia 2015, 58, 1394–1408.
8. Blaak, E.E. Carbohydrate quantity and quality and cardio-metabolic risk. Curr. Opin. Clin. Nutr. Metab. Care 2016, 19, 289–293. [CrossRef] [PubMed]
9. Papathanasopoulos, A.; Camilleri, M. Dietary fiber supplements: Effects in obesity and metabolic syndrome and relationship to gastrointestinal functions. Gastroenterology 2010, 138, 65–72. [CrossRef] [PubMed]
10. Hellström, P.M.; Grybäck, P.; Jacobsson, H. The physiology of gastric emptying. Best Pract. Res. Clin. Anaesthesiol. 2006, 20, 397–407. [CrossRef] [PubMed]
11. Phillips, L.K.; Deane, A.M.; Jones, K.L.; Rayner, C.K.; Horowitz, M. Gastric emptying and glycaemia in health and diabetes mellitus. Nat. Rev. Endocrinol. 2015, 11, 112–128. [CrossRef] [PubMed]
12. Maurer, A.H. Gastrointestinal motility, part 1: Esophageal transit and gastric emptying. J. Nucl. Med. 2015, 56, 1229–1238. [CrossRef] [PubMed]
13. Smout, A.J.P.M.; Mundt, M.W. Gastrointestinal motility testing. Best Pract. Res. Clin. Gastroenterol. 2009, 23, 287–298. [CrossRef] [PubMed]
14. Hansen, M.B. Neurohumoral control of gastrointestinal motility. Physiol. Res. 2003, 52, 1–30. [PubMed]
15. Steinert, R.E.; Feinle-Bisset, C.; Asarian, L.; Horowitz, M.; Beglinger, C.; Geary, N. Ghrelin, CCK, GLP-1, and PYY(3–36): Secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol. Rev. 2017, 97, 411–463. [CrossRef] [PubMed]
16. Hellstrom, P.M.; Naslund, E.; Edholm, T.; Schmidt, P.T.; Kristensen, J.; Theodorsson, E.; Holst, J.J.; Efendic, S. Glp-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol. Motil. 2008, 20, 649–659. [CrossRef] [PubMed]
17. Field, B.C.; Chaudhri, O.B.; Bloom, S.R. Bowels control brain: Gut hormones and obesity. Nat. Rev. Endocrinol. 2010, 6, 444–453. [CrossRef] [PubMed]
18. Lieverse, R.J.; Jansen, J.B.; Masclee, A.A.; Lamers, C.B. Satiety effects of a physiological dose of cholecystokinin in humans. Gut 1995, 36, 176–179. [CrossRef] [PubMed]
19. Collins, P.J.; Horowitz, M.; Cook, D.J.; Harding, P.E.; Shearman, D.J. Gastric emptying in normal subjects—A reproducible technique using a single scintillation camera and computer system. Gut 1983, 24, 1117–1125. [CrossRef] [PubMed]
20. Horowitz, M.; Edelbroek, M.A.L.; Wishart, J.M.; Straathof, J.W. Relationship between oral glucose-tolerance and gastric-emptying in normal healthy-subjects. Diabetologia 1993, 36, 857–862. [CrossRef] [PubMed]
21. Marathe, C.S.; Horowitz, M.; Trahair, L.G.; Wishart, J.M.; Bound, M.; Lange, K.; Rayner, C.K.; Jones, K.L. Relationships of early and late glycemic responses with gastric emptying during an oral glucose tolerance test. J. Clin. Endocrinol. Metab. 2015, 100, 3565–3571. [CrossRef] [PubMed]
22. Seimon, R.V.; Brennan, I.M.; Russo, A.; Little, T.J.; Jones, K.L.; Standfield, S.; Wishart, J.M.; Horowitz, M.; Feinle-Bisset, C. Gastric emptying, mouth-to-cecum transit, and glycemic, insulin, incretin, and energy intake responses to a mixed-nutrient liquid in lean, overweight, and obese males. Am. J. Physiol. Endocrinol. Metab. 2013, 304, E294–E300. [CrossRef] [PubMed]
23. Jones, K.L.; Horowitz, M.; Carney, B.I.; Wishart, J.M.; Guha, S.; Green, L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J. Nucl. Med. 1996, 37, 1643–1648. [PubMed]
24. Blaak, E.E.; Antoine, J.M.; Benton, D.; Bjorck, I.; Bozzetto, L.; Brouns, F.; Diamant, M.; Dye, L.; Hulshof, T.; Holst, J.J.; et al. Impact of postprandial glycaemia on health and prevention of disease. Obes. Rev. 2012, 13, 923–984. [CrossRef] [PubMed]
25. Xing, J.; Chen, J.D. Alterations of gastrointestinal motility in obesity. Obes. Res. 2004, 12, 1723–1732. [CrossRef] [PubMed]
26. Mushref, M.A.; Srinivasan, S. Effect of high fat-diet and obesity on gastrointestinal motility. Ann. Transl. Med. 2013, 1, 1–14.
27. Acosta, A.; Camilleri, M.; Shin, A.; Vazquez-Roque, M.I.; Iturrino, J.; Burton, D.; O’Neill, J.; Eckert, D.; Zinsmeister, A.R. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy. Gastroenterology 2015, 148, 537.e4–546.e4. [CrossRef] [PubMed]
28. Deloose, E.; Janssen, P.; Depoortere, I.; Tack, J. The migrating motor complex: Control mechanisms and its role in health and disease. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 271–285. [CrossRef] [PubMed]
29. Schneider, A.R.; Jepp, K.; Murczynski, L.; Biniek, U.; Stein, J. The inulin hydrogen breath test accurately reflects orocaecal transit time. Eur. J. Clin. Investig. 2007, 37, 802–807. [CrossRef] [PubMed]
30. Caride, V.J.; Prokop, E.K.; Troncale, F.J.; Buddoura, W.; Winchenbach, K.; McCallum, R.W. Scintigraphic determination of small intestinal transit time: Comparison with the hydrogen breath technique. Gastroenterology 1984, 86, 714–720. [PubMed]
31. Malagelada, C.; Malagelada, J.R. Small bowel motility. Curr. Gastroenterol. Rep. 2017, 19, 26. [CrossRef] [PubMed]
32. Saad, R.J. The wireless motility capsule: A one-stop shop for the evaluation of gi motility disorders. Curr. Gastroenterol. Rep. 2016, 18, 14. [CrossRef] [PubMed]
33. Levin, R.J. Digestion and absorption of carbohydrates–from molecules and membranes to humans. Am. J. Clin. Nutr. 1994, 59, 690s–698s. [CrossRef] [PubMed]
34. Chaikomin, R.; Wu, K.L.; Doran, S.; Jones, K.L.; Smout, A.J.; Renooij, W.; Holloway, R.H.; Meyer, J.H.; Horowitz, M.; Rayner, C.K. Concurrent duodenal manometric and impedance recording to evaluate the effects of hyoscine on motility and flow events, glucose absorption, and incretin release. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 292, G1099–G1104. [CrossRef] [PubMed]
35. Alleleyn, A.M.; van Avesaat, M.; Troost, F.J.; Masclee, A.A. Gastrointestinal nutrient infusion site and eating behavior: Evidence for a proximal to distal gradient within the small intestine? Nutrients 2016, 8, 117. [CrossRef] [PubMed]
36. Wisen, O.; Johansson, C. Gastrointestinal function in obesity: Motility, secretion, and absorption following a liquid test meal. Metabolism 1992, 41, 390–395. [CrossRef]
37. Gallagher, T.K.; Baird, A.W.; Winter, D.C. Constitutive basal and stimulated human small bowel contractility is enhanced in obesity. Ann. Surg. Innov. Res. 2009, 3, 4. [CrossRef] [PubMed]
38. Basilisco, G.; Camboni, G.; Bozzani, A.; Vita, P.; Doldi, S.; Bianchi, P.A. Orocecal transit delay in obese patients. Digest. Dis. Sci. 1989, 34, 509–512. [CrossRef] [PubMed]
39. Delgado-Aros, S.; Camilleri, M.; Garcia, M.A.; Burton, D.; Busciglio, I. High body mass alters colonic sensory-motor function and transit in humans. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G382–G388. [CrossRef] [PubMed]
40. Sarna, S.K. Colonic motility: From bench side to bedside In Integrated Systems Physiology: From Molecule to Function to Disease; Morgan & Claypool Life Sciences: San Rafael, CA, USA, 2010.
41. Bharucha, A.E. High amplitude propagated contractions. Neurogastroenterol. Motil. 2012, 24, 977–982. [CrossRef] [PubMed]
42. Riezzo, G.; Chimienti, G.; Clemente, C.; D’Attoma, B.; Orlando, A.; Mammone Rinaldi, C.; Russo, F. Colonic transit time and gut peptides in adult patients with slow and normal colonic transit constipation. Biomed. Res. Int. 2017, 2017, 3178263. [CrossRef] [PubMed]
43. Metcalf, A.M.; Phillips, S.F.; Zinsmeister, A.R.; MacCarty, R.L.; Beart, R.W.; Wolff, B.G. Simplified assessment of segmental colonic transit. Gastroenterology 1987, 92, 40–47. [CrossRef]
44. Saad, R.J.; Rao, S.S.; Koch, K.L.; Kuo, B.; Parkman, H.P.; McCallum, R.W.; Sitrin, M.D.; Wilding, G.E.; Semler, J.R.; Chey, W.D. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am. J. Gastroenterol. 2010, 105, 403–411. [CrossRef] [PubMed]
45. Eslick, G.D. Gastrointestinal symptoms and obesity: A meta-analysis. Obes. Rev. 2012, 13, 469–479. [CrossRef] [PubMed]
46. Gallagher, T.K.; Geoghegan, J.G.; Baird, A.W.; Winter, D.C. Implications of altered gastrointestinal motility in obesity. Obes. Surg. 2007, 17, 1399–1407. [CrossRef] [PubMed]
47. Delgado-Aros, S.; Locke, G.R., 3rd; Camilleri, M.; Talley, N.J.; Fett, S.; Zinsmeister, A.R.; Melton, L.J., 3rd. Obesity is associated with increased risk of gastrointestinal symptoms: A population-based study. Am. J. Gastroenterol. 2004, 99, 1801–1806. [CrossRef] [PubMed]
48. Bytzer, P.; Talley, N.J.; Leemon, M.; Young, L.J.; Jones, M.P.; Horowitz, M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: A population-based survey of 15,000 adults. Arch. Intern. Med. 2001, 161, 1989–1996. [CrossRef] [PubMed]
49. Yarandi, S.S.; Srinivasan, S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: Current status and future directions. Neurogastroenterol. Motil. 2014, 26, 611–624. [CrossRef] [PubMed]
50. Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 2012, 486, 207–214.
51. Woting, A.; Blaut, M. The intestinal microbiota in metabolic disease. Nutrients 2016, 8, 202. [CrossRef] [PubMed]
52. Tremaroli, V.; Backhed, F. Functional interactions between the gut microbiota and host metabolism. Nature 2012, 489, 242–249. [CrossRef] [PubMed]
53. Tilg, H.; Moschen, A.R. Microbiota and diabetes: An evolving relationship. Gut 2014, 63, 1513–1521. [CrossRef] [PubMed]
54. Nicholson, J.K.; Holmes, E.; Kinross, J.; Burcelin, R.; Gibson, G.; Jia, W.; Pettersson, S. Host-gut microbiota metabolic interactions. Science 2012, 336, 1262–1267. [CrossRef] [PubMed]
55. Wu, X.; Ma, C.; Han, L.; Nawaz, M.; Gao, F.; Zhang, X.; Yu, P.; Zhao, C.; Li, L.; Zhou, A.; et al. Molecular characterisation of the faecal microbiota in patients with type ii diabetes. Curr. Microbiol. 2010, 61, 69–78. [CrossRef] [PubMed]
56. Million, M.; Maraninchi, M.; Henry, M.; Armougom, F.; Richet, H.; Carrieri, P.; Valero, R.; Raccah, D.; Vialettes, B.; Raoult, D. Obesity-associated gut microbiota is enriched in lactobacillus reuteri and depleted in bifidobacterium animalis and methanobrevibacter smithii. Int. J. Obes. 2012, 36, 817–825. [CrossRef] [PubMed]
57. Zhang, X.; Shen, D.; Fang, Z.; Jie, Z.; Qiu, X.; Zhang, C.; Chen, Y.; Ji, L. Human gut microbiota changes reveal the progression of glucose intolerance. PLoS ONE 2013, 8, e71108. [CrossRef] [PubMed]
58. Pedersen, H.K.; Gudmundsdottir, V.; Nielsen, H.B.; Hyotylainen, T.; Nielsen, T.; Jensen, B.A.; Forslund, K.; Hildebrand, F.; Prifti, E.; Falony, G.; et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 2016, 535, 376–381. [CrossRef] [PubMed]
59. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergstrom, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Backhed, F. Gut metagenome in european women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99–103. [CrossRef] [PubMed]
60. Qin, J.; Li, Y.; Cai, Z.; Li, S.; Zhu, J.; Zhang, F.; Liang, S.; Zhang, W.; Guan, Y.; Shen, D.; et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 2012, 490, 55–60. [CrossRef] [PubMed]
61. Turnbaugh, P.J.; Hamady, M.; Yatsunenko, T.; Cantarel, B.L.; Duncan, A.; Ley, R.E.; Sogin, M.L.; Jones, W.J.; Roe, B.A.; Affourtit, J.P.; et al. A core gut microbiome in obese and lean twins. Nature 2009, 457, 480–484. [CrossRef] [PubMed]
62. Le Chatelier, E.; Nielsen, T.; Qin, J.; Prifti, E.; Hildebrand, F.; Falony, G.; Almeida, M.; Arumugam, M.; Batto, J.M.; Kennedy, S.; et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500, 541–546. [CrossRef] [PubMed]
63. Miquel, S.; Martin, R.; Rossi, O.; Bermudez-Humaran, L.G.; Chatel, J.M.; Sokol, H.; Thomas, M.; Wells, J.M.; Langella, P. Faecalibacterium prausnitzii and human intestinal health. Curr. Opin. Microbiol. 2013, 16, 255–261. [CrossRef] [PubMed]
64. Furet, J.-P.; Kong, L.-C.; Tap, J.; Poitou, C.; Basdevant, A.; Bouillot, J.-L.; Mariat, D.; Corthier, G.; Doré, J.; Henegar, C.; et al. Differential adaptation of human gut microbiota to bariatric surgery–induced weight loss links with metabolic and low-grade inflammation markers. Diabetes 2010, 59, 3049–3057. [CrossRef] [PubMed]
65. Yassour, M.; Lim, M.Y.; Yun, H.S.; Tickle, T.L.; Sung, J.; Song, Y.-M.; Lee, K.; Franzosa, E.A.; Morgan, X.C.; Gevers, D.; et al. Sub-clinical detection of gut microbial biomarkers of obesity and type 2 diabetes. Genome Med. 2016, 8. [CrossRef] [PubMed]
66. Zhernakova, A.; Kurilshikov, A.; Bonder, M.J.; Tigchelaar, E.F.; Schirmer, M.; Vatanen, T.; Mujagic, Z.; Vila, A.V.; Falony, G.; Vieira-Silva, S.; et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 2016, 352, 565–569. [CrossRef] [PubMed]
67. Lewis, S.J.; Heaton, K.W. Stool form scale as a useful guide to intestinal transit time. Scand. J. Gastroenterol. 1997, 32, 920–924. [CrossRef] [PubMed]
68. Cremer, J.; Segota, I.; Yang, C.; Arnoldini, M.; Sauls, J.T.; Zhang, Z.; Gutierrez, E.; Groisman, A.; Hwa, T. Effect of flow and peristaltic mixing on bacterial growth in a gut-like channel. Proc. Natl. Acad. Sci. USA 2016, 113, 11414–11419. [CrossRef] [PubMed]
69. Abrams, G.D.; Bishop, J.E. Effect of the normal microbial flora on gastrointestinal motility. Proc. Soc. Exp. Biol. Med. 1967, 126, 301–304. [CrossRef] [PubMed]
70. Anitha, M.; Vijay-Kumar, M.; Sitaraman, S.V.; Gewirtz, A.T.; Srinivasan, S. Gut microbial products regulate murine gastrointestinal motility via toll-like receptor 4 signaling. Gastroenterology 2012, 143, 1006.e4–1016.e4. [CrossRef] [PubMed]
71. Barbara, G.; Stanghellini, V.; Brandi, G.; Cremon, C.; Di Nardo, G.; De Giorgio, R.; Corinaldesi, R. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 2005, 100, 2560–2568. [CrossRef] [PubMed]
72. Husebye, E.; Hellström, P.M.; Sundler, F.; Chen, J.; Midtvedt, T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2001, 280, G368–G380. [CrossRef] [PubMed]
73. Guarino, M.P.L.; Cicala, M.; Putignani, L.; Severi, C. Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. World J. Gastroenterol. 2016, 22, 9871–9879. [CrossRef] [PubMed]
74. Zhao, Y.; Yu, Y.-B. Intestinal microbiota and chronic constipation. SpringerPlus 2016, 5, 1130. [CrossRef] [PubMed]
75. Stephen, A.M.; Wiggins, H.S.; Cummings, J.H. Effect of changing transit time on colonic microbial metabolism in man. Gut 1987, 28, 601–609. [CrossRef] [PubMed]
76. Stephen, A.M.; Cummings, J.H. The microbial contribution to human faecal mass. J. Med. Microbiol. 1980, 13, 45–56. [CrossRef] [PubMed]
77. Vandeputte, D.; Falony, G.; Vieira-Silva, S.; Tito, R.Y.; Joossens, M.; Raes, J. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 2015, 65, 57–62. [CrossRef] [PubMed]
78. Tigchelaar, E.F.; Bonder, M.J.; Jankipersadsing, S.A.; Fu, J.; Wijmenga, C.; Zhernakova, A. Gut microbiota composition associated with stool consistency. Gut 2016, 65, 540–542. [CrossRef] [PubMed]
79. Roager, H.M.; Hansen, L.B.; Bahl, M.I.; Frandsen, H.L.; Carvalho, V.; Gobel, R.J.; Dalgaard, M.D.; Plichta, D.R.; Sparholt, M.H.; Vestergaard, H.; et al. Colonic transit time is related to bacterial metabolism and mucosal turnover in the gut. Nat. Microbiol. 2016, 1, 16093. [CrossRef] [PubMed]
80. Verbeke, K.A.; Boobis, A.R.; Chiodini, A.; Edwards, C.A.; Franck, A.; Kleerebezem, M.; Nauta, A.; Raes, J.; van Tol, E.A.F.; Tuohy, K.M.; et al. Towards microbial fermentation metabolites as markers for health benefits of prebiotics. Nutr. Res. Rev. 2015, 28, 42–66. [CrossRef] [PubMed]
81. Jones, J.M. Codex-aligned dietary fiber definitions help to bridge the ‘fiber gap’. Nutr. J. 2014, 13, 34. [CrossRef] [PubMed]
82. Slavin, J. Fiber and prebiotics: Mechanisms and health benefits. Nutrients 2013, 5, 1417–1435. [CrossRef] [PubMed]
83. McKee, L.H.; Latner, T.A. Underutilized sources of dietary fiber: A review. Plant Foods Hum. Nutr. 2000, 55, 285–304. [CrossRef] [PubMed]
84. Koh-Banerjee, P.; Franz, M.; Sampson, L.; Liu, S.; Jacobs, D.R., Jr.; Spiegelman, D.; Willett, W.; Rimm, E. Changes in whole-grain, bran, and cereal fiber consumption in relation to 8-y weight gain among men. Am. J. Clin. Nutr. 2004, 80, 1237–1245. [CrossRef] [PubMed]
85. Meyer, K.A.; Kushi, L.H.; Jacobs, D.R., Jr.; Slavin, J.; Sellers, T.A.; Folsom, A.R. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. Am. J. Clin. Nutr. 2000, 71, 921–930. [CrossRef] [PubMed]
86. Schulze, M.B.; Schulz, M.; Heidemann, C.; Schienkiewitz, A.; Hoffmann, K.; Boeing, H. Fiber and magnesium intake and incidence of type 2 diabetes: A prospective study and meta-analysis. Arch. Intern. Med. 2007, 167, 956–965. [CrossRef] [PubMed]
87. Montonen, J.; Knekt, P.; Jarvinen, R.; Aromaa, A.; Reunanen, A. Whole-grain and fiber intake and the incidence of type 2 diabetes. Am. J. Clin. Nutr. 2003, 77, 622–629. [CrossRef] [PubMed]
88. Yao, B.; Fang, H.; Xu, W.; Yan, Y.; Xu, H.; Liu, Y.; Mo, M.; Zhang, H.; Zhao, Y. Dietary fiber intake and risk of type 2 diabetes: A dose-response analysis of prospective studies. Eur. J. Epidemiol. 2014, 29, 79–88. [CrossRef] [PubMed]
89. Weickert, M.O.; Mohlig, M.; Koebnick, C.; Holst, J.J.; Namsolleck, P.; Ristow, M.; Osterhoff, M.; Rochlitz, H.; Rudovich, N.; Spranger, J.; et al. Impact of cereal fibre on glucose-regulating factors. Diabetologia 2005, 48, 2343–2353. [CrossRef] [PubMed]
90. Roager, H.M.; Vogt, J.K.; Kristensen, M.; Hansen, L.B.S.; Ibrugger, S.; Maerkedahl, R.B.; Bahl, M.I.; Lind, M.V.; Nielsen, R.L.; Frokiaer, H.; et al. Whole grain-rich diet reduces body weight and systemic low-grade inflammation without inducing major changes of the gut microbiome: A randomised cross-over trial. Gut 2017. [CrossRef] [PubMed]
91. De Vries, J.; Miller, P.E.; Verbeke, K. Effects of cereal fiber on bowel function: A systematic review of intervention trials. World J. Gastroenterol. 2015, 21, 8952–8963. [CrossRef] [PubMed]
92. Lawton, C.L.; Walton, J.; Hoyland, A.; Howarth, E.; Allan, P.; Chesters, D.; Dye, L. Short term (14 days) consumption of insoluble wheat bran fibre-containing breakfast cereals improves subjective digestive feelings, general wellbeing and bowel function in a dose dependent manner. Nutrients 2013, 5, 1436–1455. [CrossRef] [PubMed]
93. Vuksan, V.; Jenkins, A.L.; Jenkins, D.J.; Rogovik, A.L.; Sievenpiper, J.L.; Jovanovski, E. Using cereal to increase dietary fiber intake to the recommended level and the effect of fiber on bowel function in healthy persons consuming north american diets. Am. J. Clin. Nutr. 2008, 88, 1256–1262. [PubMed]
94. Grundy, M.M.L.; Edwards, C.H.; Mackie, A.R.; Gidley, M.J.; Butterworth, P.J.; Ellis, P.R. Re-evaluation of the mechanisms of dietary fibre and implications for macronutrient bioaccessibility, digestion and postprandial metabolism. Br. J. Nutr. 2016, 116, 816–833. [CrossRef] [PubMed]
95. Lattimer, J.M.; Haub, M.D. Effects of dietary fiber and its components on metabolic health. Nutrients 2010, 2, 1266–1289. [CrossRef] [PubMed]
96. Weickert, M.O.; Arafat, A.M.; Blaut, M.; Alpert, C.; Becker, N.; Leupelt, V.; Rudovich, N.; Mohlig, M.; Pfeiffer, A.F. Changes in dominant groups of the gut microbiota do not explain cereal-fiber induced improvement of whole-body insulin sensitivity. Nutr. Metab. 2011, 8, 90. [CrossRef] [PubMed]
97. Slavin, J.L.; Brauer, P.M.; Marlett, J.A. Neutral detergent fiber, hemicellulose and cellulose digestibility in human subjects. J. Nutr. 1981, 111, 287–297. [CrossRef] [PubMed]
98. Vetrani, C.; Costabile, G.; Luongo, D.; Naviglio, D.; Rivellese, A.A.; Riccardi, G.; Giacco, R. Effects of whole-grain cereal foods on plasma short chain fatty acid concentrations in individuals with the metabolic syndrome. Nutrition 2016, 32, 217–221. [CrossRef] [PubMed]
99. Zhu, Y.; Sang, S. Phytochemicals in whole grain wheat and their health-promoting effects. Mol. Nutr. Food Res. 2017, 61. [CrossRef] [PubMed]
100. Dikeman, C.L.; Fahey, G.C. Viscosity as related to dietary fiber: A review. Crit. Rev. Food Sci. Nutr. 2006, 46, 649–663. [CrossRef] [PubMed]
101. Jenkins, D.J.; Marchie, A.; Augustin, L.S.; Ros, E.; Kendall, C.W. Viscous dietary fibre and metabolic effects. Clin. Nutr. Suppl. 2004, 1, 39–49. [CrossRef]
102. EFSA Panel on Dietetic Products, Nutrition and allergies (NDA). Scientific opinion on the substantiation of health claims related to beta-glucans from oats and barley and maintenance of normal blood ldl-cholesterol concentrations (ID 1236, 1299), increase in satiety leading to a reduction in energy intake (ID 851, 852), reduction of post-prandial glycaemic responses (ID 821, 824), and “digestive function” (ID 850) pursuant to article 13(1) of regulation (EC) no 1924/2006. EFSA J. 2011, 9, 2207.
103. Pal, S.; Radavelli-Bagatini, S. Effects of psyllium on metabolic syndrome risk factors. Obes. Rev. 2012, 13, 1034–1047. [CrossRef] [PubMed]
104. Gibb, R.D.; McRorie, J.W., Jr.; Russell, D.A.; Hasselblad, V.; D’Alessio, D.A. Psyllium fiber improves glycemic control proportional to loss of glycemic control: A meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus. Am. J. Clin. Nutr. 2015, 102, 1604–1614. [CrossRef] [PubMed]
105. Landin, K.; Holm, G.; Tengborn, L.; Smith, U. Guar gum improves insulin sensitivity, blood lipids, blood pressure, and fibrinolysis in healthy men. Am. J. Clin. Nutr. 1992, 56, 1061–1065. [CrossRef] [PubMed]
106. Dall’Alba, V.; Silva, F.M.; Antonio, J.P.; Steemburgo, T.; Royer, C.P.; Almeida, J.C.; Gross, J.L.; Azevedo, M.J. Improvement of the metabolic syndrome profile by soluble fibre—Guar gum—In patients with type 2 diabetes: A randomised clinical trial. Br. J. Nutr. 2013, 110, 1601–1610. [CrossRef] [PubMed]
107. Niemi, M.K.; Keinanen-Kiukaanniemi, S.M.; Salmela, P.I. Long-term effects of guar gum and microcrystalline cellulose on glycaemic control and serum lipids in type 2 diabetes. Eur. J. Clin. Pharmacol. 1988, 34, 427–429. [CrossRef] [PubMed]
108. Uusitupa, M.; Tuomilehto, J.; Karttunen, P.; Wolf, E. Long term effects of guar gum on metabolic control, serum cholesterol and blood pressure levels in type 2 (non-insulin-dependent) diabetic patients with high blood pressure. Ann. Clin. Res. 1984, 16 (Suppl. 43), 126–131. [PubMed]
109. Wanders, A.J.; van den Borne, J.J.; de Graaf, C.; Hulshof, T.; Jonathan, M.C.; Kristensen, M.; Mars, M.; Schols, H.A.; Feskens, E.J. Effects of dietary fibre on subjective appetite, energy intake and body weight: A systematic review of randomized controlled trials. Obes. Rev. 2011, 12, 724–739. [CrossRef] [PubMed]
110. Wang, G.J.; Tomasi, D.; Backus, W.; Wang, R.; Telang, F.; Geliebter, A.; Korner, J.; Bauman, A.; Fowler, J.S.; Thanos, P.K.; et al. Gastric distention activates satiety circuitry in the human brain. NeuroImage 2008, 39, 1824–1831. [CrossRef] [PubMed]
111. Blackburn, N.A.; Holgate, A.M.; Read, N.W. Does guar gum improve post-prandial hyperglycaemia in humans by reducing small intestinal contact area? Br. J. Nutr. 1984, 52, 197–204. [CrossRef] [PubMed]
112. Lentle, R.G.; Janssen, P.W. Physical characteristics of digesta and their influence on flow and mixing in the mammalian intestine: A review. J. Comp. Physiol. B 2008, 178, 673–690. [CrossRef] [PubMed]
113. Wisen, O.; Hellstrom, P.M. Gastrointestinal motility in obesity. J. Intern. Med. 1995, 237, 411–418. [CrossRef] [PubMed]
114. Schwartz, S.E.; Levine, R.A.; Weinstock, R.S.; Petokas, S.; Mills, C.A.; Thomas, F.D. Sustained pectin ingestion: Effect on gastric emptying and glucose tolerance in non-insulin-dependent diabetic patients. Am. J. Clin. Nutr. 1988, 48, 1413–1417. [CrossRef] [PubMed]
115. Schwartz, S.E.; Levine, R.A.; Singh, A.; Scheidecker, J.R.; Track, N.S. Sustained pectin ingestion delays gastric emptying. Gastroenterology 1982, 83, 812–817. [PubMed]
116. Sanaka, M.; Yamamoto, T.; Anjiki, H.; Nagasawa, K.; Kuyama, Y. Effects of agar and pectin on gastric emptying and post-prandial glycaemic profiles in healthy human volunteers. Clin. Exp. Pharmacol. Physiol. 2007, 34, 1151–1155. [CrossRef] [PubMed]
117. Torsdottir, I.; Alpsten, M.; Holm, G.; Sandberg, A.S.; Tolli, J. A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. J. Nutr. 1991, 121, 795–799. [CrossRef] [PubMed]
118. Thondre, P.S.; Shafat, A.; Clegg, M.E. Molecular weight of barley beta-glucan influences energy expenditure, gastric emptying and glycaemic response in human subjects. Br. J. Nutr. 2013, 110, 2173–2179. [CrossRef] [PubMed]
119. Frost, G.S.; Brynes, A.E.; Dhillo, W.S.; Bloom, S.R.; McBurney, M.I. The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal. Eur. J. Clin. Nutr. 2003, 57, 293–298. [CrossRef] [PubMed]
120. Juvonen, K.R.; Purhonen, A.K.; Salmenkallio-Marttila, M.; Lahteenmaki, L.; Laaksonen, D.E.; Herzig, K.H.; Uusitupa, M.I.; Poutanen, K.S.; Karhunen, L.J. Viscosity of oat bran-enriched beverages influences gastrointestinal hormonal responses in healthy humans. J. Nutr. 2009, 139, 461–466. [CrossRef] [PubMed]
121. Karhunen, L.J.; Juvonen, K.R.; Flander, S.M.; Liukkonen, K.H.; Lahteenmaki, L.; Siloaho, M.; Laaksonen, D.E.; Herzig, K.H.; Uusitupa, M.I.; Poutanen, K.S. A psyllium fiber-enriched meal strongly attenuates postprandial gastrointestinal peptide release in healthy young adults. J. Nutr. 2010, 140, 737–744. [CrossRef] [PubMed]
122. Dikeman, C.L.; Murphy, M.R.; Fahey, G.C., Jr. Dietary fibers affect viscosity of solutions and simulated human gastric and small intestinal digesta. J. Nutr. 2006, 136, 913–919. [CrossRef] [PubMed]
123. Abbasi, N.N.; Purslow, P.P.; Tosh, S.M.; Bakovic, M. Oat beta-glucan depresses SGLT1- and GLUT2-mediated glucose transport in intestinal epithelial cells (IEC-6). Nutr. Res. 2016, 36, 541–552. [CrossRef] [PubMed]
124. Schonfeld, J.; Evans, D.F.; Wingate, D.L. Effect of viscous fiber (guar) on postprandial motor activity in human small bowel. Dig. Dis. Sci. 1997, 42, 1613–1617. [CrossRef] [PubMed]
125. Van Nieuwenhoven, M.A.; Kovacs, E.M.; Brummer, R.J.; Westerterp-Plantenga, M.S.; Brouns, F. The effect of different dosages of guar gum on gastric emptying and small intestinal transit of a consumed semisolid meal. J. Am. Coll. Nutr. 2001, 20, 87–91. [CrossRef] [PubMed]
126. Bianchi, M.; Capurso, L. Effects of guar gum, ispaghula and microcrystalline cellulose on abdominal symptoms, gastric emptying, orocaecal transit time and gas production in healthy volunteers. Dig. Liver Dis. 2002, 34 (Suppl. 2), S129–S133. [CrossRef]
127. Fuller, S.; Beck, E.; Salman, H.; Tapsell, L. New horizons for the study of dietary fiber and health: A review. Plant Foods Hum. Nutr. 2016, 71, 1–12. [CrossRef] [PubMed]
128. Gibson, G.R.; Hutkins, R.; Sanders, M.E.; Prescott, S.L.; Reimer, R.A.; Salminen, S.J.; Scott, K.; Stanton, C.; Swanson, K.S.; Cani, P.D.; et al. Expert consensus document: The international scientific association for probiotics and prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat. Rev. Gastroenterol. Hepatol. 2017, 14, 491–502. [CrossRef] [PubMed]
129. Flamm, G.; Glinsmann, W.; Kritchevsky, D.; Prosky, L.; Roberfroid, M. Inulin and oligofructose as dietary fiber: A review of the evidence. Crit. Rev. Food Sci. Nutr. 2001, 41, 353–362. [CrossRef] [PubMed]
130. Ramirez-Farias, C.; Slezak, K.; Fuller, Z.; Duncan, A.; Holtrop, G.; Louis, P. Effect of inulin on the human gut microbiota: Stimulation of bifidobacterium adolescentis and faecalibacterium prausnitzii. Br. J. Nutr. 2009, 101, 541–550. [CrossRef] [PubMed]
131. Davis, L.M.; Martinez, I.; Walter, J.; Goin, C.; Hutkins, R.W. Barcoded pyrosequencing reveals that consumption of galactooligosaccharides results in a highly specific bifidogenic response in humans. PLoS ONE 2011, 6, e25200. [CrossRef] [PubMed]
132. Roberfroid, M. Prebiotics: The concept revisited. J. Nutr. 2007, 137, 830s–837s. [CrossRef] [PubMed]
133. Delzenne, N.M.; Cani, P.D.; Neyrinck, A.M. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: Experimental data. J. Nutr. 2007, 137, 2547s–2551s. [CrossRef] [PubMed]
134. Delzenne, N.M.; Neyrinck, A.M.; Cani, P.D. Modulation of the gut microbiota by nutrients with prebiotic properties: Consequences for host health in the context of obesity and metabolic syndrome. Microb. Cell. Fact. 2011, 10 (Suppl. 1), S10. [CrossRef] [PubMed]
135. Cani, P.D.; Lecourt, E.; Dewulf, E.M.; Sohet, F.M.; Pachikian, B.D.; Naslain, D.; De Backer, F.; Neyrinck, A.M.; Delzenne, N.M. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal. Am. J. Clin. Nutr. 2009, 90, 1236–1243. [CrossRef] [PubMed]
136. Vulevic, J.; Juric, A.; Tzortzis, G.; Gibson, G.R. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. J. Nutr. 2013, 143, 324–331. [CrossRef] [PubMed]
137. Dewulf, E.M.; Cani, P.D.; Claus, S.P.; Fuentes, S.; Puylaert, P.G.; Neyrinck, A.M.; Bindels, L.B.; de Vos, W.M.; Gibson, G.R.; Thissen, J.P.; et al. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013, 62, 1112–1121. [CrossRef] [PubMed]
138. Pedersen, C.; Gallagher, E.; Horton, F.; Ellis, R.J.; Ijaz, U.Z.; Wu, H.; Jaiyeola, E.; Diribe, O.; Duparc, T.; Cani, P.D.; et al. Host-microbiome interactions in human type 2 diabetes following prebiotic fibre (galacto-oligosaccharide) intake. Br. J. Nutr. 2016, 116, 1869–1877. [CrossRef] [PubMed]
139. Canfora, E.E.; van der Beek, C.M.; Hermes, G.D.; Goossens, G.H.; Jocken, J.W.; Holst, J.J.; van Eijk, H.M.; Venema, K.; Smidt, H.; Zoetendal, E.G.; et al. Supplementation of diet with galacto-oligosaccharides increases bifidobacteria, but not insulin sensitivity, in obese prediabetic individuals. Gastroenterology 2017, 135, 87–97. [CrossRef] [PubMed]
140. Liu, F.; Prabhakar, M.; Ju, J.; Long, H.; Zhou, H.W. Effect of inulin-type fructans on blood lipid profile and glucose level: A systematic review and meta-analysis of randomized controlled trials. Eur. J. Clin. Nutr. 2017, 71, 9–20. [CrossRef] [PubMed]
141. Delzenne, N.M.; Cani, P.D.; Everard, A.; Neyrinck, A.M.; Bindels, L.B. Gut microorganisms as promising targets for the management of type 2 diabetes. Diabetologia 2015, 58, 2206–2217. [CrossRef] [PubMed]
142. Gomes, J.M.G.; Costa, J.A.; Alfenas, R.C.G. Metabolic endotoxemia and diabetes mellitus: A systematic review. Metabolism 2017, 68, 133–144. [CrossRef] [PubMed]
143. Kootte, R.S.; Vrieze, A.; Holleman, F.; Dallinga-Thie, G.M.; Zoetendal, E.G.; de Vos, W.M.; Groen, A.K.; Hoekstra, J.B.; Stroes, E.S.; Nieuwdorp, M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes. Metab. 2012, 14, 112–120. [CrossRef] [PubMed]
144. Holscher, H.D. Dietary fiber and prebiotics and the gastrointestinal microbiota. Gut Microbes 2017, 8, 172–184. [CrossRef] [PubMed]
145. Cummings, J.H.; Macfarlane, G.T. Gastrointestinal effects of prebiotics. Br. J. Nutr. 2002, 87 (Suppl. 2), S145–S151. [CrossRef] [PubMed]
146. Russo, F.; Riezzo, G.; Chiloiro, M.; De Michele, G.; Chimienti, G.; Marconi, E.; D’Attoma, B.; Linsalata, M.; Clemente, C. Metabolic effects of a diet with inulin-enriched pasta in healthy young volunteers. Curr. Pharm. Des. 2010, 16, 825–831. [CrossRef] [PubMed]